HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Somasekar, A Articles by Alcolado, R Search for Related Content PubMed PubMed Citation Articles by Somasekar, A Articles by Alcolado, R

Genital condylomata in a patient receiving infliximab for Crohn’s disease

Department of Gastroenterology, Royal Glamorgan Hospital, Llantrisant, UK

Correspondence to:
Correspondence to:
Dr R Alcolado
Royal Glamorgan Hospital, Llantrisant CF72 8XR, Wales, UK; ruthalcolado{at}btinternet.com

Infliximab is a monoclonal antibody against tumour necrosis factor-alpha. Recent studies have shown that it is effective in treating patients with refractory Crohn’s disease and in those with Crohn’s fistulae. Though this drug is found to be safe in clinical trials, sporadic reports of serious complications have been recorded in the literature. The case of a patient who developed profuse genital warts after infliximab treatment is reported. The literature is reviewed and information is presented on side effects and complications as a result of infliximab therapy.

Keywords: Crohn’s disease; infliximab; condylomata